B2M and neoplasm: By downregulating MHC class I expression or interfering with antigen processing pathways, such as by lacking TAP or losing beta-2 microglobulin (B2M), which impairs peptide presentation and decreases visibility to CD8+ T cells, tumor cells avoid immune detection [5].